open access

Vol 69, No 3 (2018)
Original paper
Submitted: 2017-09-30
Accepted: 2017-12-22
Published online: 2018-04-13
Get Citation

A study of the application of EZSCAN in pilots and in the general population

Ling Li, Xin-Yan Wang, Shu-Qiang Jiang, Yu-Hong Qin, Yan-Yan Zhou
·
Pubmed: 29952415
·
Endokrynol Pol 2018;69(3):259-263.

open access

Vol 69, No 3 (2018)
Original Paper
Submitted: 2017-09-30
Accepted: 2017-12-22
Published online: 2018-04-13

Abstract

Objective: This study aims to evaluate EZSCAN detection in pilots and the general population, and determine the significance of EZSCAN detection in the identification of a pilot’s health. Methods: A total of 87 cases of non-diabetic Air Force pilots (pilot group) and 49 cases from the general population without diabetes were collected. These two groups of subjects underwent EZSCAN detection, as well as the detection of blood glucose, lipid and uric acid levels. Results: Subjects in the pilot group had the highest detection rate of no risk and the lowest detection rate of high risk, while the general population had the highest detection rate of high risk, followed by low risk. The difference in diabetic risk between these two groups were statistically significant (P < 0.01). Various indicators were compared according to different risk levels. In the no risk group, age, BMI and the triglyceride of pilots were lower than in the general population; and the difference was statistically significant (P < 0.05). In high risk group, BMI and blood uric acid of pilots were lower than in the general population; and the difference was statistically significant (P < 0.05). Conclusions: BMI and blood uric acid are positively correlated to diabetic risk. The EZSCAN detection system can be used for assessment of pilot’s diabetic risk, and has certain significance in a pilot’s health identification.

Abstract

Objective: This study aims to evaluate EZSCAN detection in pilots and the general population, and determine the significance of EZSCAN detection in the identification of a pilot’s health. Methods: A total of 87 cases of non-diabetic Air Force pilots (pilot group) and 49 cases from the general population without diabetes were collected. These two groups of subjects underwent EZSCAN detection, as well as the detection of blood glucose, lipid and uric acid levels. Results: Subjects in the pilot group had the highest detection rate of no risk and the lowest detection rate of high risk, while the general population had the highest detection rate of high risk, followed by low risk. The difference in diabetic risk between these two groups were statistically significant (P < 0.01). Various indicators were compared according to different risk levels. In the no risk group, age, BMI and the triglyceride of pilots were lower than in the general population; and the difference was statistically significant (P < 0.05). In high risk group, BMI and blood uric acid of pilots were lower than in the general population; and the difference was statistically significant (P < 0.05). Conclusions: BMI and blood uric acid are positively correlated to diabetic risk. The EZSCAN detection system can be used for assessment of pilot’s diabetic risk, and has certain significance in a pilot’s health identification.
Get Citation

Keywords

EZSCAN, pilots, health check-up populations, diabetes risk assessment

About this article
Title

A study of the application of EZSCAN in pilots and in the general population

Journal

Endokrynologia Polska

Issue

Vol 69, No 3 (2018)

Article type

Original paper

Pages

259-263

Published online

2018-04-13

Page views

2177

Article views/downloads

884

DOI

10.5603/EP.a2018.0027

Pubmed

29952415

Bibliographic record

Endokrynol Pol 2018;69(3):259-263.

Keywords

EZSCAN
pilots
health check-up populations
diabetes risk assessment

Authors

Ling Li
Xin-Yan Wang
Shu-Qiang Jiang
Yu-Hong Qin
Yan-Yan Zhou

References (22)
  1. Xu Y, Bi YF, Wang WQ. China's adult diabetes epidemic and control situation — In 2010 China monitor chronic diseases and diabetes project survey report. The Endocrine Metabolism. 2014; 30(3): 184–186.
  2. Endocrinology branch of Chinese medical association. Chinese adults with type 2 diabetes prevention expert consensus. The Endocrine Metabolism. 2014; 30(4): 277–283.
  3. Hubert D, Brunswick P, Calvet JH, et al. Abnormal electrochemical skin conductance in cystic fibrosis. J Cyst Fibros. 2011; 10(1): 15–20.
  4. Schwarz P, Brunswick P, Calvet JH. EZSCANTM A New Technology to Detect Diabetes Risk. British Journal of Diabetes & Vascular Disease. 2010; 11(4): 204–209.
  5. Ramachandran A, Moses A, Shetty S, et al. A new non-invasive technology to screen for dysglycaemia including diabetes. Diabetes Res Clin Pract. 2010; 88(3): 302–306.
  6. American Diabetes Association. Standards of Medical Care in Diabetes 2008. Diabetes Care. 2004; 31(Supplement 1): S12–S54.
  7. American Diabetes Association. Standards of Medical Care in Diabetes 2010. Diabetes Care. 2010; 33(Supplement 1): S11–S61.
  8. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ. 2001; 322(7292): 986–988.
  9. Mayaudon H, Miloche PO, Bauduceau B. A new simple method for assessing sudomotor function: relevance in type 2 diabetes. Diabetes Metab. 2010; 36(6 Pt 1): 450–454.
  10. Sheng CS, Zeng WF, Huang QF, et al. Accuracy of a Novel Non-Invasive technology based EZSCAN system for the diagnosis of diabetes mellitus in Chinese. Diabetol Metab Syndr. 2011; 3(1): 36.
  11. Schwarz PEH, Brunswick P, Calvet JH. EZSCANTM a new technology to detect diabetes risk. The British Journal of Diabetes & Vascular Disease. 2011; 11(4): 204–209.
  12. Chen L, Chen X, Ding R, et al. Evaluation of EZSCAN as a screening tool for impaired glucose metabolism. Diabetes Res Clin Pract. 2013; 100(2): 210–214.
  13. Liu HJ, Xu XR, Cheng J. 2003–2008 Ariations fighter pilots unqualified analysis. The Chinese Aerospace Medical Journal. 2009; 20(3): 173–176.
  14. Wang BR, Xu XR, Zhai LH. A comparative study of different model of flight crew grounded disease(2006—2012). The People's Liberation Army Medical Journals . 2014; 35(4): 308–311.
  15. Men K, Jiang Y, Xiao D. The pilot ariations annual check-up comparative analysis. The Chinese Aerospace Medical Journal. 2014; 25(3): 161–166.
  16. Yang Z, Xu B, Lu J, et al. Autonomic test by EZSCAN in the screening for prediabetes and diabetes. PLoS One. 2013; 8(2): e56480.
  17. Xiaohui X. The impact of obesity in managing diabetes. Journal of Chinese Pharmaceutical Sciences. 2015; 24(6).
  18. Gray N, Picone G, Sloan F, et al. Relation between BMI and diabetes mellitus and its complications among US older adults. South Med J. 2015; 108(1): 29–36.
  19. Sabin MA, Magnussen CG, Juonala M, et al. Insulin and BMI as predictors of adult type 2 diabetes mellitus. Pediatrics. 2015; 135(1): e144–e151.
  20. Bao W, Yeung E, Tobias DK, et al. Long-term risk of type 2 diabetes mellitus in relation to BMI and weight change among women with a history of gestational diabetes mellitus: a prospective cohort study. Diabetologia. 2015; 58(6): 1212–1219.
  21. Yang W, Lu J, Weng J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362(12): 1090–1101.
  22. Ramachandran A, Moses A, Snehalatha C, et al. Assessment of Sudomotor Function to Predict Future Abnormalities of Glucose Tolerance in at Risk Population. Journal of Diabetes & Metabolism. 2011; 02(03).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl